Physician profile
Mani Mahdyoon
NPI 1144232349
$13,582.76
in general payments reported to CMS, 2019-2025
45 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,460 · 2020: $2,445 · 2021: $2,475 · 2022: $1,420 · 2023: $1,380 · 2024: $1,767 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,782.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,587.99 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $1,537.36 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $931.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $858.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $856.16 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $772.05 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $717.36 | 2019-2022 | |
| Pfizer INC. | $704.07 | 2019-2025 | |
| Abbvie INC. | $702.27 | 2019-2025 | |
| Forte Bio-Pharma LLC | $600.84 | 2020-2023 | Prolate, Nalocet |
| Novartis Pharmaceuticals Corporation | $525.26 | 2019-2025 | |
| Mylan Specialty L.P. | $517.40 | 2019-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $449.09 | 2019-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $244.39 | 2019-2023 | Eliquis |
| Esperion Therapeutics, INC. | $241.92 | 2020-2024 | Nexletol |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mani Mahdyoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.